



Dan Meek

Dan Meek, Entrepreneur in Residence and Director of Bioscience Commercialization, is responsible for TechColumbus' business incubation services and business consulting for medical device and life science companies in the 15-county region of central Ohio. Since joining TechColumbus in 2008, he has assisted several companies in growing their businesses and raising follow-on capital from angel and venture capital sources.

Dan's background includes start-up experience in the specialty pharmaceutical and medical device industries. Dan was Director of Program Management and Senior Director of Product Development for Ventaira Pharmaceuticals, a venture-backed company in Columbus that developed a novel respiratory inhaler and new inhalation drug therapies. His experience includes product development, clinical and regulatory affairs, project management, and intellectual property development.

Prior to Ventaira, Dan was with Battelle Memorial Institute as a Senior Research Scientist where he was responsible for development of device technologies for the treatment of lung cancer, acute respiratory distress syndrome, and asthma. Several of these technologies developed led to the formation of Ventaira Pharmaceuticals.



Burton Page

Burton Page is Sr. Director of Technology Commercialization. Burton brings a wealth of experience in corporate strategy and policy, business development and regulatory affairs, with a particular focus on the pharmaceutical, vaccine, and diagnostic industries. He is well-versed in the commercialization of new healthcare products and services, especially the creation of joint ventures, licensing agreements, and other strategic business relationships.

Prior to joining TechColumbus he was engaged by QED Technologies, a business development consulting firm for small cap life science companies, where he reviewed, drafted and negotiated various business development agreements. Prior to QED, Mr. Page was Director, Public Policy for SmithKline Beecham (SB), now GlaxoSmithKline, where he provided strategic analysis to SB's pharmaceutical, vaccine, diagnostic and pharmacy benefit management businesses to leverage the Company's products and services through public sector programs and initiatives. He also served as Counsel for SB, providing legal advice to the clinical laboratory and pharmaceutical divisions on commercial, regulatory and legislative matters. Prior to SB, Mr. Page served as a healthcare attorney for two Philadelphia law firms, where he specialized in commercial transactions, business planning, and regulatory matters for the firm's corporate and institutional clients.

Mr. Page holds a Juris Doctor degree from Temple University School of Law, a Master of Science degree in Health Policy and Administration from The Pennsylvania State University, and a Bachelor of Arts degree from the University of North Carolina at Chapel Hill.



Susan A. Stanton, Ph.D.

Susan Stanton is Technology Commercialization Consultant with TechColumbus. Susan has more than 20 years experience in commercializing technology. She has held positions in Fortune 50 companies, such as Alcoa, and Bayer, startups, government and education. She was Vice President, Market and Technology Assessment at the National Technology Transfer Center (WV) where she led a group of 30 researchers and was responsible for assessing technologies and evaluating markets for the Center's clients and developed new programs, processes, and products to meet their growing needs. Recognizing a need for assisting technology based businesses with aligning their technology commercialization strategy with the corporate strategic plan, Susan started SBCi Ltd. in 1999. She has assisted businesses and entrepreneurs in identifying, evaluating and commercializing technology based innovations.

Susan received her Bachelor of Science degree in Chemistry from Millersville University and her Master of Philosophy degree in Organic Chemistry from Syracuse University. She was awarded the Ph. D. in Organic Chemistry from the University of Rochester. She has several publications and numerous patents in adhesive formulation, catalysis and use, and electronics. Susan is an active member in the American Chemical Society and the Licensing Executives Society. She has served on several association and foundation boards.